Browse diseases

…sults A total of 529 AMD and 261 DME patients were analysed. In AMD, 276 patients were treated with aflibercept and 253 with ranibi…

…macular degeneration (nAMD), diabetic macular oedema (DME), and retinal vein occlusion (RVO). In the last 5 years, new molecules, extended dosing inte…

…ment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). Unlike previous anti-VEGF agents, faricimab targets both…

…the treatment of wet age-related macular degeneration (AMD) and diabetic macular oedema (DME) in adults.Aim and Objectives To evaluate the use of aflib…

…l dexamethasone implants are used in hospital settings to treat diabetic macular oedema (DME) and macular oedema secondary to retinal vein occlusion (R…

…acy and safety of faricimab for treatment-naïve and pre-treated diabetic macular oedema (DME) in a real-world setting.Methods This multicentre, retrosp…

… medications allowed the inclusion of patients with more severe T2D who could be on semaglutide as third or even fourth-line treatm…

…to anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME).Methods Multicentric, retrospective, case-series study in patie…

…as age-related macular degeneration (AMD) (68.97%), followed by diabetic macular oedema (DME) (30.17%) and retinal vein occlusion (RVO) (0.86%). Most p…

…Background and Importance Treatment burden in neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) is an issue for patien…

…lucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes mellitus (T2D), has potential associations with higher rates of diabetic retin…

…nd compare the risk of adverse renal events among patients with diabetic macular oedema (DME) who were treated with either intravitreal ranibizumab or aflibe…